On March 25, 2024, upon the previously announced consummation of the transactions contemplated by that certain Asset Purchase Agreement (the ?Asset Purchase Agreement?), dated as of February 5, 2024, between Ayala Pharmaceuticals, Inc. and Immunome, Inc. (?Purchaser?), Andres Guttierez, the Company?s Chief Medical Officer and Executive Vice President, departed the Company.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.665 USD | +19.82% | +16.26% | -0.30% |
Chiffre d''affaires - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-0.30% | 23.66M | |
+2.19% | 42.75B | |
+47.70% | 41.61B | |
+11.69% | 41.34B | |
-8.83% | 26.59B | |
+6.48% | 25.49B | |
-23.03% | 18.12B | |
+30.28% | 12.24B | |
-2.21% | 11.76B | |
+9.22% | 11B |
- Stock Market
- Equities
- ADXS Stock
- News Ayala Pharmaceuticals, Inc.
- Andres Guttierez, Chief Medical Officer and Executive Vice President, Departs from Ayala Pharmaceuticals, Inc